GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

sotrovimab   Click here for help

GtoPdb Ligand ID: 11333

Synonyms: GSK-4182136 | GSK4182136 | VIR-7831 | VIR7831 | Xevudy®
Approved drug
sotrovimab is an approved drug (UK & EMA (2021))
Compound class: Antibody
Comment: Sotrovimab (VIR-7831) is a monoclonal antibody that binds to a highly conserved epitope within the surface spike glycoprotein of sarbecoviruses. The parental antibody, from which sotrovimab was derived, was originally identified in the memory B cells of a patient who had recovered from SARS-CoV infection. Sotrovimab was progressed by GSK and Vir Biotechnology as a COVID-19 therapeutic [4]. Sotrovimab retains some activity against the omicron BA.1 (B.1.1.529) SARS-CoV-2 variant (bioRxiv preprint [1]), but it activity against the BA.2 omicron subvariant is lower [3].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. UK MHRA (2021)  |  EU EMA (2021)
International Nonproprietary Names Click here for help
INN number INN
11766 sotrovimab
Synonyms Click here for help
GSK-4182136 | GSK4182136 | VIR-7831 | VIR7831 | Xevudy®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1110
Other databases
GtoPdb PubChem SID 434321768
Search PubMed clinical trials sotrovimab
Search PubMed titles sotrovimab
Search PubMed titles/abstracts sotrovimab